Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: Survival Estimates From the EMPA-REG OUTCOME Trial

著录项

• 来源
  《Circulation: An Official Journal of the American Heart Association》 |2018年第15期|共3页
• 作者

  Claggett Brian; Lachin John M.; Hantel Stefan; Fitchett David; Inzucchi Silvio E.; Woerle Hans J.; George Jyothis T.; Zinman Bernard;

  展开▼
• 作者单位

  Brigham &

  Womens Hosp Div Cardiovasc Med 75 Francis St Boston MA 02115 USA;

  George Washington Univ Biostat Ctr Rockville MD USA;

  Boehringer Ingelheim Pharma GmbH &

  Co KG Biberach Germany;

  St Michaels Hosp Div Cardiol Toronto ON Canada;

  Yale Univ Endocrinol Sect Sch Med New Haven CT USA;

  Boehringer Ingelheim Int GmbH Ingelheim Germany;

  Boehringer Ingelheim Int GmbH Ingelheim Germany;

  Univ Toronto Toronto ON Canada;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 心脏、血管（循环系）疾病;
• 关键词

  cardiovascular diseases; diabetes mellitus; empagliflozin;

  机译：心血管疾病;糖尿病;Empagliflozin;